Niva Bupa Health Insurance Company Limited has received an order from the Income Tax Department raising a demand of ₹28,37,45,380 for Assessment Year 2023-24, including ₹7,10,47,664 in interest. The company disclosed this on March 15, 2026.
The demand is linked to disallowed marketing expenses and claim provisions, issues that reportedly affect the wider insurance industest.
Impact and Industest Context
This tax demand is a significant financial liability for Niva Bupa, likely affecting its profitability and cash flow. The reasons for the demand suggest that the company’s accounting for substantial operational costs like marketing expenses and provisions for incurred but not reported (IBNR) and incurred but not enough reported (IBNER) claims is under scrutiny. Since these issues are reportedly common across the industest, how Niva Bupa’s appeal progresses could offer insights for other Indian health insurers.
Previous Tax Issues
Niva Bupa has encountered similar tax challenges before. In April 2025, the company received a Notice of Demand for ₹16.71 crore for Assessment Year 2022-23, also citing disallowed marketing expenses and claim provisions.
Major general insurer ICICI Lombard General Insurance has faced much larger tax demands for similar reasons, totalling over ₹3,453 crore for income tax and ₹273 crore for GST, highlighting scrutiny across the insurance sector.
Company Focus Shifts
The company must now concentrate on its legal strategy to contest the tax demand. Management’s focus will now be split between maintaining daily operations and managing the appeal. This potential liability will be an important consideration for the company’s financial planning and risk assessment.
Potential Financial Risks
The main risk lies with the outcome of the appeal. If unsuccessful, Niva Bupa will be required to pay the full demand plus any accrued interest. There’s a potential strain on liquidity and profits if the demand can’t be fully managed or offset.
Industest Comparisons
Star Health and Allied Insurance Company Ltd., India’s largest private health insurer, operates in the same competitive space. As of December 2024, Star Health held a 44% market share among standalone health insurers.
Looking Ahead
Investors and stakeholders will closely watch Niva Bupa’s appeal progress at the Income Tax Appellate Tribunal or other relevant bodies. Any updates from the company on the appeal grounds and strategy will be key. The tax authorities’ approach to these widespread disallowances will also be important to observe.
Disclaimer:This content
is for educational and informational purposes only and does not constitute investment, financial, or
trading advice, nor a recommconcludeation to purchase or sell any securities. Readers should consult a
SEBI-registered advisor before creating investment decisions, as markets involve risk and past performance
does not guarantee future results. The publisher and authors accept no liability for any losses. Some
content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views
expressed do not reflect the publication’s editorial stance.
Leave a Reply